期刊文献+

血浆纤溶活性测定在冠心病中的意义 被引量:7

Importance of fibrinolytic activity in patients with coronary artery diseases
下载PDF
导出
摘要 目的 研究血浆纤溶活性与冠脉病变程度、范围及稳定性的关系。方法 根据受累冠脉数、狭窄程度及病变稳定性将 2 56例患者分别进行分组 ,测定并比较各组患者的组织型纤溶酶原激活物 (tissueplasminogenactivator,t-PA)及纤溶酶原激活物抑制剂 (plasminogenactivatorinhibitor- 1 ,PAI- 1 )血浆浓度。结果 ①不稳定型心绞痛组患者血浆PAI- 1活性高于稳定型心绞痛组患者 (1 3 64± 2 32vs 6 2 2± 1 78,P <0 0 1 ) ;②多支冠脉病变组患者血浆PAI - 1活性高于单支病变组患者(1 1 67± 2 1 2vs 6 38± 1 72 ,P <0 0 1 ) ;③堵塞组患者较狭窄组患者血浆PAI- 1活性显著升高 (1 2 69± 1 82vs 8 38± 1 82 ,P<0 0 1 ) ;④冠脉粥样病变的范围、程度及稳定性与血浆t-PA活性没有明显关系。结论 血浆PAI - 1活性对冠脉病变的范围。 Objective To study the correlation of fibrinolytic activity to the area,extent,and stability of coronary artery culprit lesion.Methods In 256 patients undergoing coronary angiography,tissue plasminogen activator(t-PA) & plasminogen activator inhibitor-1(PAI-1) were measured with usual procedures.Results ①There was a positive association between PAI-1 and unstable angina (13 64±2 32 vs 6 22±1 78, P <0 01);②A strong relationship between PAI-1 and the area and extent of coronary artery disease was found (11 67±2 12 vs 6 38±1 72 & 12 69±1 82 vs 8 38±1 82, P <0 01);③There was no relation between t-PA and the severity of coronary artery culprit lesion.Conclusion Elevated PAI-1 may predisposes to the area,extent and destabilization of culprit lesion in coronary artery.
出处 《中国急救医学》 CAS CSCD 北大核心 2002年第1期6-7,共2页 Chinese Journal of Critical Care Medicine
基金 湖北省"九五"重点攻关项目基金资助 (NO 96 2P110 1)
  • 相关文献

参考文献6

  • 1[1]Moreno PR,Falk E,Palacios IF,et al.Macrophage infiltration in acute coronary syndromes:implications for plaque rupture[J].Circulation,1994,90:2844-2850.
  • 2[2]Gardenan A,Lohre J,Katz N,et al.The 4G/4G genotype of the plasminogen activator inhibitor 4G/5G gene polymorphism is associated with coronary athrosis in patients at high risk for this disease[J].Throm Haemost,1999,82:1121-1126.
  • 3[3]Padro T,Emeis JJ,Steins M,et al.Quantification of plasminogen activators and their inhibitors in the aortic vessel wall in relation to the presence and severity of atherosclerotic disease[J].Arterioscler Thromb Vasc Biol,1995,15:893-902.
  • 4[4]Declerck PJ,Alessi MC,Verstreken MV,et al.Measurement of plasminogen activator inhibitor-1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay[J].Blood,1988,71:220-225.
  • 5[5]Nicholas OG,Michael W,Mansfield JW,et al.Plasminogen activator inhibitor-1 promoter 4G/5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterized by coronry angiography[J].Arterioscler Thromb Vasc Biol,1997,17:33-37.
  • 6[6]Wieczored I,Ludlam CA,Fox KAA.Tissue-type plasminogen activator and plasminogen activator activities as predictors of adverse events in unstable angina[J].Am J Cardiol,1994,74:424-429.

同被引文献87

引证文献7

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部